BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

pharmafile | October 15, 2018 | News story | Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma 

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, failing to significantly improve overall survival (OS) in patients who had relapsed following platinum-based chemotherapy.

The trial examined the drug’s efficacy in two randomised groups, with one receiving Opdivo and the other using either topotecan or amrubicin. The primary endpoint was OS, while secondary endpoints included progression-free survival and objective response rates.

Despite being found to not provide sufficient OS benefit versus chemotherapy alone in this indication, the study found the safety profile of the PD-1 inhibitor to be consistent with previous findings.

“Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” commented Dr Sabine Maier, Development Lead, Thoracic Cancers, Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate -331 study.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

Latest content